SAN DIEGO, June 25, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced a
Cooperative Research and Development Agreement (CRADA) with the
National Institute of Allergy and Infectious Diseases' Vaccine
Research Center (VRC), part of the National Institutes of Health,
enabling the VRC's use of Halozyme's ENHANZE® drug
delivery technology to develop subcutaneous formulations of broadly
neutralizing antibodies (bnAbs) against HIV for HIV treatment.
The two bnAbs selected for the CRADA are VRC07-523LS and N6LS.
The VRC will engage in early phase studies in healthy adults
investigating the safety, tolerability, dose, and pharmacokinetics
of formulating these bnAbs with ENHANZE® for the purpose
of optimizing subcutaneous administration of these antibodies.
"We are excited to collaborate with NIAID as they seek to
develop new therapies that potentially address a large unmet need
in the field of HIV treatment and prevention," said Dr.
Helen Torley, President and CEO of
Halozyme. "This CRADA is an example of the value
ENHANZE® can potentially bring to the treatment of
infectious diseases, particularly in the early stages of
development."
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery
technology is based on its patented recombinant human hyaluronidase
enzyme (rHuPH20). rHuPH20 has been shown to remove traditional
limitations on the volume of biologics that can be delivered
subcutaneously (just under the skin). By using rHuPH20, some
biologics and compounds that are administered intravenously may
instead be delivered subcutaneously. ENHANZE® may also
benefit subcutaneous biologics by reducing the need for multiple
injections. This delivery has been shown in studies to reduce
health care practitioner time required for administration and
shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies,
including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Halozyme contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, statements concerning the possible activity, benefits
and attributes of ENHANZE®, the possible method of action of
ENHANZE®, its potential application to aid in the dispersion and
absorption of other injected therapeutic drugs, including broadly
neutralizing antibodies, and statements concerning certain other
potential benefits of ENHANZE® including facilitating more rapid
delivery of injectable medications through subcutaneous delivery.
These forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including uncertainties concerning whether
collaborative products potentially identified under the subject
CRADA are ultimately developed or commercialized, unexpected
expenditures and costs, unexpected results or delays in development
and regulatory review, unexpected regulatory approval requirements,
unexpected adverse events and competitive conditions. These and
other factors that may result in differences are discussed in
greater detail in Halozyme's most recent Annual and Quarterly
Reports filed with the Securities and Exchange Commission. Except
as required by law, Halozyme undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-crada-with-national-institute-of-allergy-and-infectious-diseases-for-use-of-enhanze-drug-delivery-technology-300873766.html
SOURCE Halozyme Therapeutics, Inc.